Literature DB >> 24931705

Restoring mood balance in depression: ketamine reverses deficit in dopamine-dependent synaptic plasticity.

Pauline Belujon1, Anthony A Grace2.   

Abstract

BACKGROUND: One of the most novel and exciting findings in major depressive disorder research over the last decade is the discovery of the fast-acting and long-lasting antidepressant effects of ketamine. Indeed, the therapeutic effects of classic antidepressants, such as selective serotonin reuptake inhibitors, require a month or longer to be expressed, with about a third of major depressive disorder patients resistant to treatment. Clinical studies have shown that a low dose of ketamine exhibits fast-acting relatively sustained antidepressant action, even in treatment-resistant patients. However, the mechanisms of ketamine action at a systems level remain unclear.
METHODS: Wistar-Kyoto rats were exposed to inescapable, uncontrollable footshocks. To evaluate learned helplessness behavior, we used an active avoidance task in a shuttle box equipped with an electrical grid floor. After helplessness assessment, we performed in vivo electrophysiological recordings first from ventral tegmental area dopaminergic (DA) neurons and second from accumbens neurons responsive to fimbria stimulation. Ketamine was injected and tested on helpless behavior and electrophysiological recordings.
RESULTS: We show that ketamine is able to restore the integrity of a network by acting on the DA system and restoring synaptic dysfunction observed in stress-induced depression. We show that part of the antidepressant effect of ketamine is via the DA system. Indeed, injection of ketamine restores a decreased dopamine neuron population activity, as well as synaptic plasticity (long-term potentiation) in the hippocampus-accumbens pathway, via, in part, activation of D1 receptors.
CONCLUSIONS: This work provides a unique systems perspective on the mechanisms of ketamine on a disrupted limbic system.
Copyright © 2014 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dopamine; ketamine; learned helplessness; nucleus accumbens; synaptic plasticity; ventral tegmental area

Mesh:

Substances:

Year:  2014        PMID: 24931705      PMCID: PMC4223010          DOI: 10.1016/j.biopsych.2014.04.014

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  51 in total

1.  Amygdala-ventral pallidum pathway decreases dopamine activity after chronic mild stress in rats.

Authors:  Chun-Hui Chang; Anthony A Grace
Journal:  Biol Psychiatry       Date:  2013-09-28       Impact factor: 13.382

Review 2.  Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants.

Authors:  Jason M Dwyer; Ronald S Duman
Journal:  Biol Psychiatry       Date:  2013-01-04       Impact factor: 13.382

3.  A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia.

Authors:  Kathryn M Gill; Daniel J Lodge; James M Cook; Shamim Aras; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2011-05-11       Impact factor: 7.853

4.  Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression.

Authors:  Hiroyuki Koike; Michihiko Iijima; Shigeyuki Chaki
Journal:  Behav Brain Res       Date:  2011-06-06       Impact factor: 3.332

5.  Role of the prefrontal cortex in altered hippocampal-accumbens synaptic plasticity in a developmental animal model of schizophrenia.

Authors:  Pauline Belujon; Mary H Patton; Anthony A Grace
Journal:  Cereb Cortex       Date:  2012-12-12       Impact factor: 5.357

Review 6.  Are you or aren't you? Challenges associated with physiologically identifying dopamine neurons.

Authors:  Mark A Ungless; Anthony A Grace
Journal:  Trends Neurosci       Date:  2012-03-28       Impact factor: 13.837

7.  Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar-Kyoto rats.

Authors:  Y Tizabi; B H Bhatti; K F Manaye; J R Das; L Akinfiresoye
Journal:  Neuroscience       Date:  2012-04-19       Impact factor: 3.590

8.  Different stressors produce excitation or inhibition of mesolimbic dopamine neuron activity: response alteration by stress pre-exposure.

Authors:  Ornella Valenti; Kathryn M Gill; Anthony A Grace
Journal:  Eur J Neurosci       Date:  2012-04       Impact factor: 3.386

9.  D₁-NMDA receptor interactions in the rat nucleus accumbens change during adolescence.

Authors:  Frédéric Huppé-Gourgues; Patricio O'Donnell
Journal:  Synapse       Date:  2012-02-22       Impact factor: 2.562

10.  Dopamine neurons modulate neural encoding and expression of depression-related behaviour.

Authors:  Kay M Tye; Julie J Mirzabekov; Melissa R Warden; Emily A Ferenczi; Hsing-Chen Tsai; Joel Finkelstein; Sung-Yon Kim; Avishek Adhikari; Kimberly R Thompson; Aaron S Andalman; Lisa A Gunaydin; Ilana B Witten; Karl Deisseroth
Journal:  Nature       Date:  2012-12-12       Impact factor: 49.962

View more
  87 in total

1.  α7 nicotinic receptor full agonist reverse basolateral amygdala hyperactivity and attenuation of dopaminergic neuron activity in rats exposed to chronic mild stress.

Authors:  Gilda A Neves; Anthony A Grace
Journal:  Eur Neuropsychopharmacol       Date:  2019-10-12       Impact factor: 4.600

2.  Diazepam reverses increased anxiety-like behavior, social behavior deficit, and dopamine dysregulation following withdrawal from acute amphetamine.

Authors:  Millie Rincón-Cortés; Kimberly G Gagnon; Hannah K Dollish; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2018-06-18       Impact factor: 7.853

3.  Rapid Antidepressant Action and Restoration of Excitatory Synaptic Strength After Chronic Stress by Negative Modulators of Alpha5-Containing GABAA Receptors.

Authors:  Jonathan Fischell; Adam M Van Dyke; Mark D Kvarta; Tara A LeGates; Scott M Thompson
Journal:  Neuropsychopharmacology       Date:  2015-04-22       Impact factor: 7.853

Review 4.  Dopamine and addiction: what have we learned from 40 years of research.

Authors:  Marcello Solinas; Pauline Belujon; Pierre Olivier Fernagut; Mohamed Jaber; Nathalie Thiriet
Journal:  J Neural Transm (Vienna)       Date:  2018-12-19       Impact factor: 3.575

5.  Evidence for an anterior-posterior differentiation in the human hippocampal formation revealed by meta-analytic parcellation of fMRI coordinate maps: focus on the subiculum.

Authors:  Henry W Chase; Mareike Clos; Sofia Dibble; Peter Fox; Anthony A Grace; Mary L Phillips; Simon B Eickhoff
Journal:  Neuroimage       Date:  2015-03-14       Impact factor: 6.556

Review 6.  Pathogenesis of depression: Insights from human and rodent studies.

Authors:  C Ménard; G E Hodes; S J Russo
Journal:  Neuroscience       Date:  2015-05-30       Impact factor: 3.590

Review 7.  Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.

Authors:  Saurabh S Kokane; Ross J Armant; Carlos A Bolaños-Guzmán; Linda I Perrotti
Journal:  Behav Brain Res       Date:  2020-02-13       Impact factor: 3.332

8.  Female rats are resistant to the long-lasting neurobehavioral changes induced by adolescent stress exposure.

Authors:  Katharina Klinger; Felipe V Gomes; Millie Rincón-Cortés; Anthony A Grace
Journal:  Eur Neuropsychopharmacol       Date:  2019-07-29       Impact factor: 4.600

Review 9.  Treatment-resistant depression: are animal models of depression fit for purpose?

Authors:  Paul Willner; Catherine Belzung
Journal:  Psychopharmacology (Berl)       Date:  2015-08-21       Impact factor: 4.530

10.  Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters.

Authors:  Adem Can; Panos Zanos; Ruin Moaddel; Hye Jin Kang; Katinia S S Dossou; Irving W Wainer; Joseph F Cheer; Douglas O Frost; Xi-Ping Huang; Todd D Gould
Journal:  J Pharmacol Exp Ther       Date:  2016-07-28       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.